Response-driven movement control with AUSTEDO1

Multiple therapeutic dosing options

Dial representing multiple dosing options that can range from 24mg/day to 48mg/day.

In the FIRST-HD clinical trial, the mean daily dose of AUSTEDO after titration phase was 40 mg/day1

AUSTEDO offers dosing options to help patients effectively and tolerably reach symptom control1

Please see additional dosing and administration information at the bottom of this page.

AUSTEDO dosing should increase until symptom control is tolerably achieved1

Start treatment at 6 mg /day

Blue arrow pointing right Blue arrow pointing right

Increase by 6 mg/day weekly until desired symptom control is reached

Ascending bar graph representing the titration schedule through Week 8 for patients with HD chorea. Ascending bar graph representing the titration schedule through Week 8 for patients with HD chorea. Ascending bar graph representing the titration schedule through Week 8 for patients with HD chorea.

AUSTEDO is available in 6-mg, 9-mg, and 12-mg tablets1

6 mg AUSTEDO®  (deutetrabenazine) tablet. 9 mg AUSTEDO®  (deutetrabenazine) tablet. 12 mg AUSTEDO®  (deutetrabenazine) tablet.

Tablets not shown at actual size.

Blue glass icon.

Additional dosing and administration information1

  • Administer total daily dosages above 6 mg/day in 2 divided doses
  • AUSTEDO should be taken with food
  • AUSTEDO should be swallowed whole. Tablets should not be chewed, crushed, or broken

REFERENCE: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc.